Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 11 to 20 of 333 total matches.

Penpulimab (Anniko) for Nasopharyngeal Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination ...
Penpulimab-kcqx (Anniko – Akeso Biopharma), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with cisplatin or carboplatin plus gemcitabine for first-line treatment of recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma and for use as monotherapy for metastatic disease in adults with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Penpulimab is the second immune checkpoint inhibitor to be approved in the US for treatment of nasopharyngeal carcinoma;...
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e122-3   doi:10.58347/tml.2025.1733k |  Show IntroductionHide Introduction

Prevention and Treatment of Sunburn

   
The Medical Letter on Drugs and Therapeutics • Jun 07, 2004  (Issue 1184)
block at least part of UVA II in addition to UVB. SUN AVOIDANCE — Avoiding exposure to direct sunlight ...
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn. UVA has been implicated in the development of phototoxicity and photoaging. The FDA permits sunscreen manufacturers to claim broad-spectrum protection if their products block at least part of UVA II in addition to UVB.

Click here to view the free full article.
Med Lett Drugs Ther. 2004 Jun 7;46(1184):45-6 |  Show IntroductionHide Introduction

Retifanlimab (Zynyz) for Anal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
(Zynyz – Incyte), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with carboplatin and paclitaxel for first-line treatment of unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as monotherapy in patients who had disease progression or intolerance to platinum-based chemotherapy. The drug received accelerated approval for treatment of recurrent locally advanced or metastatic Merkel cell carcinoma in 2023.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e126-7   doi:10.58347/tml.2025.1733m |  Show IntroductionHide Introduction

Maestro Rechargeable System for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016  (Issue 1493)
electrical pulses to block vagus nerve signals between the stomach and the brain. According ...
The FDA has approved the Maestro Rechargeable System (EnteroMedics), a subcutaneously implanted device, for use in adults who have not been able to lose weight with a weight loss program within the past 5 years and who have a body mass index (BMI) of 40 to 45, or a BMI ≥35 and at least one obesity-related comorbidity.
Med Lett Drugs Ther. 2016 Apr 25;58(1493):54-5 |  Show IntroductionHide Introduction

Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
on dialysis. Tenapanor was used as monotherapy in two of the trials (BLOCK, PHREEDOM) and in addition ...
The FDA has approved the sodium/hydrogen exchanger 3 (NHE3) inhibitor tenapanor (Xphozah – Ardelyx) to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy when phosphate binders are ineffective or as monotherapy when phosphate binders cannot be tolerated. Tenapanor is the first NHE3 inhibitor to be approved in the US for hyperphosphatemia. It was previously approved as Ibsrela to treat irritable bowel syndrome with constipation (IBS-C).
Med Lett Drugs Ther. 2024 Mar 4;66(1697):38-9   doi:10.58347/tml.2024.1697b |  Show IntroductionHide Introduction

Rocuronium - A New Neuromuscular Blocker

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994  (Issue 928)
short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available ...
Rocuronium bromide (Zemuron - Organon), a new short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available in the USA for intravenous use. It is being promoted particularly for use in rapid endotracheal intubation.
Med Lett Drugs Ther. 1994 Aug 5;36(928):71-2 |  Show IntroductionHide Introduction

Irbesartan for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 1998  (Issue 1019)
, blocks the binding of angiotensin II to type 1 angiotensin II receptors. Angiotensin-converting-enzyme ...
Irbesartan (Avapro - Sanofi/Bristol-Myers Squibb) is the third angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension. Losartan (Cozaar) and valsartan (Diovan) were marketed earlier. Eprosartan (Teveten - SmithKline Beecham) has been approved by the FDA but not marketed.
Med Lett Drugs Ther. 1998 Jan 30;40(1019):18-9 |  Show IntroductionHide Introduction

Opdualag for Metastatic Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA ...
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo), a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA for treatment of unresectable or metastatic melanoma in patients ≥12 years old. Relatlimab, which is only available in combination with nivolumab, is the first LAG-3 blocking antibody to become available in the US. Immune checkpoint inhibitors, including the anti-CTLA-4 antibody ipilimumab (Yervoy) and the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20   doi:10.58347/tml.2023.1668g |  Show IntroductionHide Introduction

Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024  (Issue 1694)
Biosciences), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with cisplatin and gemcitabine for first-line treatment of recurrent locally advanced or metastatic nasopharyngeal carcinoma and for use as monotherapy for treatment of recurrent unresectable or metastatic nasopharyngeal carcinoma in adults with disease progression on or after platinum-based chemotherapy. It is the first immune checkpoint inhibitor to be approved in the US for treatment of nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7   doi:10.58347/tml.2024.1694e |  Show IntroductionHide Introduction

Candesartan for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998  (Issue 1040)
— Candesartan, like irbesartan, losartan and valsartan, blocks the binding of angiotensin II to type 1 ...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.
Med Lett Drugs Ther. 1998 Nov 20;40(1040):109-10 |  Show IntroductionHide Introduction